Time is running out to nominate your women’s cancer innovators

The Femtech World Awards are celebrating the innovators revolutionising the way we diagnose and treat cancer in women.

Cancer is a major public health and economic issue.

Female breast cancer is the most commonly diagnosed cancer in the world, with an estimated 2.3 million cases diagnosed globally in 2020 alone.

However, what once seemed impossible in cancer research is now a reality thanks to a number of technological innovations that have led to breakthroughs in the ways we diagnose, understand and treat cancer.

Through the Women’s Cancer Innovation Award, Femtech World aims to shine a light on the organisations devoted to transforming the future of cancer care for women worldwide.

The Women’s Cancer Innovation Award is one of 10 categories open for entry, all of which seek to acknowledge excellence in femtech and reward the dedication, commitment and innovation of those working in the space. 

The Women’s Cancer Innovation Award is sponsored by Endomag.

Endomag believes everyone deserves a better standard of cancer care – that’s why they design their cancer localisation technologies with both the clinician and patient in mind.

Many leading hospitals across the world use their unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is.

Their Magseed marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace lymphatic tracer is the world’s first, long-lasting, non-radioactive dual tracer for lymphatic mapping.

Paired with the Sentimag localisation platform, they have now been widely proven across over 200 clinical studies, featuring more than 20,000 patients.

Entry for the Women’s Cancer Innovation award and all other categories closes on April 17.

Find out more and enter for free here.